Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (18431)	4/1/1998 11:52:00 AM
From: tuck	Read Replies (3) \| Respond to of 32384

Bernie, I should re-emphasize that a triglyceride spike per daily dose is not something the FDA will enjoy seeing, particularly in diabetics. Thus approval is not a slam dunk. This is why my source considers it the only real achilles heel of the compounds. If memory serves me well, the spike occurs a few hours after the dose, and lasts an hour or two. Sorry, I don't have numbers. Ligand is trying to find a way around this, but I am not sure the mechanism is understood yet. Anyone know if other drugs can ameliorate this problem? I am not sure Henry accepts the existence of the problem at this time, so our Chief Science Officer hasn't yet commented, to my knowledge. This has been a good lesson: inside info that's any use is too dangerous. Speaking of dangerous, the reason we try not to anger each other: we are partners in rock climbing, and having an angry belayer is not good. Anyhow, enjoy a good stiff . . . drink! Tuck